

Please note: This document was created automatically and is not a substitute for the manufacturer's original document.

Product Datasheet

TBI-223, CAS [[2071265-08-0]]

MCE-HY-139398

Article Name	TBI-223, CAS [[2071265-08-0]]
Biozol Catalog Number	MCE-HY-139398
Supplier Catalog Number	HY-139398
Alternative Catalog Number	MCE-HY-139398-100MG,MCE-HY-139398-50MG,MCE-HY-139398-25MG,MCE-HY-139398-10MG,MCE-HY-139398-5MG,MCE-HY-139398-10MMX1ML
Manufacturer	MedchemExpress
Category	Biochemikalien
Product Description	TBI-223 is an orally active oxazolidinone antibiotic and an antimicrobial. TBI-223 shows activity against <i>Mycobacterium tuberculosis</i> (Mtb). TBI-223 exhibits an IC50 of 68 µg/mL for inhibiting mitochondrial protein synthesis (MPS) in HepG2 cells. TBI-223 is currently in development for the treatment of drug-resistant tuberculosis. It has been shown to be effective against multidrug-resistant Mtb strains. TBI-223 is also being evaluated for its potential use in the treatment of other bacterial infections, such as pneumonia and sepsis. The mechanism of action of TBI-223 is believed to involve the inhibition of mitochondrial protein synthesis, which disrupts the cellular energy production and leads to cell death. TBI-223 is a pro-drug that is converted to its active form by esterases in the body. It has a relatively short half-life of approximately 2 hours. TBI-223 is currently in phase I clinical trials for the treatment of drug-resistant tuberculosis. It has been shown to be well-tolerated and to have a favorable safety profile. TBI-223 is a promising new antibiotic that has the potential to revolutionize the treatment of drug-resistant tuberculosis and other bacterial infections.
Molecular Weight	365.36
Purity	99.73
CAS Number	[2071265-08-0]
Formula	C17H20FN3O5
Target	Antibiotic, Bacterial
Application Notes	MCE Product type: Reference compound1